Adial Q2 net loss widens to $51.99 million from year-ago quarter

Reuters2026/08/14 20:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Adial posted a GAAP net loss of USD 51.99 million for the quarter ended June 30, 2026, versus a USD 1.96 million loss a year earlier.
Operating loss widened to USD 52.03 million from USD 1.88 million, driven by a USD 46.19 million acquired in-process R&D charge.
General and administrative costs more than quadrupled to USD 5.4 million on merger-related costs, bonus and severance; R&D fell 40% to USD 440,000.
Cash and cash equivalents totaled USD 28.7 million at June 30, 2026; net cash used in operations rose to USD 7.98 million.
Pipeline focus shifted to AT177 for ulcerative colitis after the Azora acquisition; IND filing targeted for Q2 2027, proof-of-concept readout expected H1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090051), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Adial Q2 net loss widens to $51.99 million from year-ago quarter

You may also like

Crypto prices